Thus, quantifying DMN suppression, a phenomenon characterized by rich cognitive activity, may provide a basis for developing potential biomarkers to characterize AD as well as at‐risk populations such as MCI and asymptomatic APOE‐ε4 allele carriers (Filippini et al., 2009). Here, APOE is linked to Alzheimer disease.